We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+16.48%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.7B
AUM Growth
+$1.25B
(+12%)
Cap. Flow
-$79.9M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
34.47%
Holding
156
New
27
Increased
33
Reduced
24
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$208M |
| 2 |
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
|
+$109M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$74.8M |
| 4 |
BLUE
bluebird bio
BLUE
|
+$56.1M |
| 5 |
Cardinal Health
CAH
|
+$54.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$191M |
| 2 |
AGN
Allergan Inc
AGN
|
+$158M |
| 3 |
Merck
MRK
|
+$149M |
| 4 |
Biogen
BIIB
|
+$113M |
| 5 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$106M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.37% |
| 2 | Technology | 0.15% |
| 3 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$130B
| $573M | 4.89% |
8,882,800
+1,194,100
| +16% | +$74.8M |
|
|
2
Biogen
BIIB
$31.5B
| $510M | 4.35% |
1,206,800
-287,900
| -19% | -$113M |
|
3
Amgen
AMGN
$211B
| $487M | 4.16% |
3,049,000
+341,000
| +13% | +$53.7M |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $470M | 4.01% |
1,578,187
+89,987
| +6% | +$25.7M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $366M | 3.12% |
3,172,000
-485,600
| -13% | -$58M |
|
6
Gilead Sciences
GILD
$166B
| $335M | 2.86% |
3,411,400
-838,100
| -20% | -$85.1M |
|
7
HCA Healthcare
HCA
$92B
| $332M | 2.83% |
4,408,000
+100,000
| +2% | +$7.18M |
|
|
SHPG
8
DELISTED
Shire pic
SHPG
| $331M | 2.83% |
1,385,000
+215,000
| +18% | +$49.4M |
|
|
RLYP
9
DELISTED
RELYPSA INC COM
RLYP
| $319M | 2.73% |
8,857,551
| – | – |
|
|
ICPT
10
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $316M | 2.7% |
1,120,000
-365,000
| -25% | -$79M |
|
|
IPXL
11
DELISTED
Impax Laboratories, Inc.
IPXL
| $313M | 2.67% |
6,678,000
| – | – |
|
|
MDVN
12
DELISTED
MEDIVATION, INC.
MDVN
| $303M | 2.59% |
4,697,800
+160,000
| +4% | +$9.17M |
|
13
AbbVie
ABBV
$472B
| $282M | 2.41% |
4,814,900
-516,200
| -10% | -$31.2M |
|
14
Thermo Fisher Scientific
TMO
$215B
| $243M | 2.08% |
1,811,700
+216,000
| +14% | +$27.8M |
|
15
Cooper Companies
COO
$14.2B
| $242M | 2.06% |
5,162,000
+279,600
| +6% | +$11.8M |
|
16
Incyte
INCY
$25.2B
| $240M | 2.05% |
2,622,500
-526,800
| -17% | -$43.5M |
|
|
17
Boston Scientific
BSX
$69.4B
| $240M | 2.05% |
13,511,000
+13,191,000
| +4,122% | +$208M |
|
|
HNT
18
DELISTED
HEALTH NET INC
HNT
| $234M | 1.99% |
3,861,400
+150,000
| +4% | +$8.45M |
|
19
Molina Healthcare
MOH
$10.6B
| $233M | 1.99% |
3,459,100
-122,800
| -3% | -$7.1M |
|
20
Neurocrine Biosciences
NBIX
$18.2B
| $232M | 1.98% |
5,833,600
-135,000
| -2% | -$4.83M |
|
21
Illumina
ILMN
$29.1B
| $223M | 1.91% |
1,236,684
-281,261
| -19% | -$53M |
|
22
Intuitive Surgical
ISRG
$128B
| $207M | 1.77% |
3,687,300
-272,700
| -7% | -$15.4M |
|
23
Perrigo
PRGO
$1.45B
| $207M | 1.76% |
1,247,800
| – | – |
|
24
Ironwood Pharmaceuticals
IRWD
$596M
| $192M | 1.64% |
14,342,447
| – | – |
|
25
Regeneron Pharmaceuticals
REGN
$73B
| $190M | 1.63% |
421,800
+31,600
| +8% | +$13.4M |
|
Similar funds
HSA
NL
BPWM
LFG
JIM
CTC
PAMP
SGM
OrbiMed's Q1 2015 Portfolio in Review
As of Q1 2015, OrbiMed held 156 positions worth $11.7B, up 12% from $10.5B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
OrbiMed's Q1 2015 filing shows 27 new, 33 increased, 24 reduced and 20 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M. The largest sale was Vertex Pharmaceuticals, an estimated $191M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier, followed by Technology and Financials.
- OrbiMed's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 104,200 shares worth $105M.
- OrbiMed added most to Boston Scientific in Q1 2015, an estimated $208M increase.
- OrbiMed's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $191M.
- OrbiMed fully exited Allergan Inc in Q1 2015, selling an estimated $158M.
- OrbiMed's ten largest holdings make up 34% of its $11.7B portfolio in Q1 2015.
- OrbiMed opened 27 new positions and closed 20 in Q1 2015.
- OrbiMed's portfolio value rose 12% quarter-over-quarter to $11.7B.
Based on OrbiMed's 13F filing for Q1 2015, filed 15 May 2015.